Targeted
Protein
Degradation
[ News ]
- 2021.06.30
- UBiECNE successfully completed the 1st close of the seed round.
- 2021.03.31
- UBiENCE has completed its role as a supporting company for ACT-MS with NIHS.
- 2021.03.30
- Settlement of Accounts
Our Science
SNIPER: Specific and Non-genetic IAP-dependent Protein ERaser
IAPs are frequently overexpressed in tumor cells,
which is involved in resistance to tumor therapy
Company Overview
- Name
- UBiENCE Inc.
- Address
- 8F Nihonbashi Life Science Building7 1-9-10 Nihonbashi-horidomecho, Chuo-ku, Tokyo 103-0012, JAPAN
- Business Summary
- Discovery and Development of Pharmaceutical Compounds
- Established
- April 20, 2018
- Capitalization
- 227,320,000Yen
- Employees
- 3
- URL
- https://www.ubience.com/
- Fiscal Year
- December
- Board of Directors
-
President Yasuhiro IWATA
Director Nobuyuki TAKAHASHI
Director, Co-founder Hirobumi TAKEUCHI
- Company Auditors
- Atsuko SUYAMA